McIntyre, Freedman & Flynn Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

McIntyre, Freedman & Flynn Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$266K	Hold	426	–	–	0.16%	68
2026 Q1	$329K	Hold	426	–	–	0.19%	62
2025 Q4	$329K	Hold	426	–	–	0.21%	62
2025 Q3	$240K	Buy	+426	New	+$241K	0.14%	68

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

McIntyre, Freedman & Flynn Investment Advisers's REGN Position: Q2 2026 in Review

McIntyre, Freedman & Flynn Investment Advisers held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 426 shares worth $266K. The position accounts for 0.16% of the portfolio, ranked #68.

McIntyre, Freedman & Flynn Investment Advisers first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. The position peaked at $329K in Q1 2026. 955 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

McIntyre, Freedman & Flynn Investment Advisers held 426 shares of Regeneron Pharmaceuticals worth $266K as of Q2 2026.
McIntyre, Freedman & Flynn Investment Advisers left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up 0.16% of McIntyre, Freedman & Flynn Investment Advisers's portfolio in Q2 2026, its #68 holding.
McIntyre, Freedman & Flynn Investment Advisers first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
McIntyre, Freedman & Flynn Investment Advisers's Regeneron Pharmaceuticals position peaked at $329K in Q1 2026.
955 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on McIntyre, Freedman & Flynn Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.